Klinische Studien zur Verbesserung der Prognose von Postinfarktpatienten mittels antiarrhythmischer Therapie

  • K. Rathgen
Conference paper

Zusammenfassung

Für die Prognose des Postinfarktpatienten sind der klinischen Erfahrung entsprechend und durch zahlreiche Literaturmitteilungen belegt zwei voneinander unabhängige Faktoren bestimmend: das Ausmaß der linksventrikulären Funktionseinschränkung bzw. die verbleibende linksventrikuläre Funktion und das Auftreten ventrikulärer Arrhythmien.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bastian BC, Macfarlane P W, McLauchlan JH, Ballantyne D, Clark R, Hillis WS, Rae AP, Hutton I (1980) A prospective randomized trial of tocainide in patients following myocardial infarction. Am Heart J 100: 1017–1022PubMedCrossRefGoogle Scholar
  2. 2.
    Bennett MA, Wilner JM, Pentecost BL (1970) Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet 2: 909–911PubMedCrossRefGoogle Scholar
  3. 3.
    Chamberlain DA, Jewitt DE, Julian DG, Campbell RWF, Boyle DMcC, Shanks RG (1980) Oral mexiletine in high risk patients after myocardial infarction. Lancet 2: 1324–1327PubMedCrossRefGoogle Scholar
  4. 4.
    Collaborative group (1971) Phenytoin after recovery from myocardial infarction. Controlled trial in 568 patients. Lancet 2: 1055–1057Google Scholar
  5. 5.
    Darby S, Bennett MA, Cruickshank JC, Pentecost BL (1972) Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet 1: 817–819PubMedCrossRefGoogle Scholar
  6. 6.
    Gottlieb SH, Achuff SC, Mellits ED, Gerstenblith G, Banghman KL, Becker L, Chandra NC, Henley S, Humphries JO, Heck C, Kennedy MM, Weisfeldt ML, Reid PR (1987) Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. Circulation 75: 792–799PubMedCrossRefGoogle Scholar
  7. 7.
    Hagemeijer F, Van Durme JP, Lubsen J, Bogaert M, Hugenholtz DG (1983) Antiarrhythmic prevention of sudden death in patients with complex ventricular arrhythmias after acute myocardial infarction: the Ghent-Rotterdam aprindine study. Eur Heart J 1: 964–966Google Scholar
  8. 8.
    Holmberg S, Bergmann H (1967) Prophylactic quinidine treatment in myocardial infarction: a double blind study. Acta med scand 181: 297–304PubMedCrossRefGoogle Scholar
  9. 9.
    IMPACT research group (1984) International mexiletine and placebo antiarrhythmic coronary trial: 1. report on arrhythmia and other findings. J Am Coll Cardiol 4: 1148–1163CrossRefGoogle Scholar
  10. 10.
    Jennings G, Model DG, Jones MBS, Turner PP, Besterman EMM; Kidner PH (1976) Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. Lancet 1: 51–54PubMedCrossRefGoogle Scholar
  11. 11.
    Jones DT, Kostuk WJ, Gunton RW (1974) Prophylactic quinidine for the prevention of arrhythmias after acute myocardial infarction. Am J Cardiol 33: 655–660PubMedCrossRefGoogle Scholar
  12. 12.
    Koch-Weser J, Klein SW, Foo-Canto U, Kastor JA, De Sanctis RW (1969) Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. N Engl J Med 281: 1253–1260PubMedCrossRefGoogle Scholar
  13. 13.
    Lie KI, Wellens HJJ, van Capelle FJ, Durrer D (1974) Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. N Engl J Med 291: 1324–1326PubMedCrossRefGoogle Scholar
  14. 14.
    Lie KI, Liem KL, Louridtz WJ, Janse WJ, Willebrands AF, Durrer D (1978) Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. Am J Cardiol 42: 486–488PubMedCrossRefGoogle Scholar
  15. 15.
    Nicholls DP, Haybyrne T, Barnes PC (1980) Intravenous and oral disopyramide after myocardial infarction. Lancet 2: 936–938PubMedCrossRefGoogle Scholar
  16. 16.
    O’Brien KP, Taylor PM, Croxson RS (1973) Prophylactic lidocaine in hospital patients with acute myocardial infarction. Med J Aust 2 (Suppl): 36–37PubMedGoogle Scholar
  17. 17.
    Peter T, Ross D, Duffield A, Luxton M, Harper R, Hunt D, Sloman G (1978) Effect of survival after myocardial infarction of long-term treatment with Phenytoin. Br Heart J 40: 1356–1360PubMedCrossRefGoogle Scholar
  18. 18.
    Pitt S, Lipp H, Anderson ST (1971) Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet 1: 612–616PubMedCrossRefGoogle Scholar
  19. 19.
    Raynell PC (1961) Prophylactic procaine amide in myocardial infarction. Br Heart J 23: 421–424CrossRefGoogle Scholar
  20. 20.
    Ryden L, Amman K, Conradson TB, Hofvendahl S, Mortensen O, Smedgard P (1980) Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. Am Heart J 100: 1006–1012PubMedCrossRefGoogle Scholar
  21. 21.
    Valentine PA, Frew JL, Mashford ML, Sloman JG (1974) Lidocaine in the prevention of sudden death in the prehospital phase of acute infarction. A double-blind study. N Engl J Med 291: 1327–1331Google Scholar
  22. 22.
    Wilcox RG, Rowley JM, Hampton JR, Mitchell JRA, Roland JM, Banks DC (1980) Randomized placebo-controlled trial comparing Oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet 2: 764–769Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1991

Authors and Affiliations

  • K. Rathgen
    • 1
  1. 1.Abteilung für Kardiologie, 1. Medizinische KlinikChristian-Albrechts-Universität KielKielGermany

Personalised recommendations